Effectiveness and safety of switching biologics after secukinumab treatment failure in moderate-to-severe plaque psoriasis: a retrospective cohort study - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Evaluating the Safety and Efficacy of Switching to Alternative Biologics Following Secukinumab Treatment Failure in Patients with Moderate-to-Severe Plaque Psoriasis: A Retrospective Cohort Analysis
Clinical Scorecard: Evaluating the Safety and Efficacy of Switching to Alternative Biologics Following Secukinumab Treatment Failure in Patients with Moderate-to-Severe Plaque Psoriasis: A Retrospective Cohort Analysis
At a Glance
Category
Detail
Condition
Moderate-to-severe plaque psoriasis
Key Mechanisms
Switching from secukinumab to ixekizumab, guselkumab, or ustekinumab
Target Population
Patients with moderate-to-severe plaque psoriasis who failed secukinumab
Care Setting
Dermatology department
Key Highlights
Ixekizumab showed higher PASI 75 response rates at week 12 compared to guselkumab and ustekinumab.
Adverse event rates were mild and did not require treatment discontinuation.
Guselkumab offers gradual but sustained improvement.
The choice of switching strategy should consider failure type and patient preference.
Guideline-Based Recommendations
Diagnosis
Diagnosis of moderate-to-severe plaque psoriasis according to the Chinese Guidelines for Psoriasis Diagnosis and Treatment.
Management
Switching to ixekizumab, guselkumab, or ustekinumab after secukinumab failure.
Monitoring & Follow-up
Follow-up for at least 12 weeks after switching to assess treatment response.
Risks
Adverse events associated with ixekizumab, guselkumab, and ustekinumab were reported, with rates of 28.6%, 12.5%, and 33.3%, respectively.
Patient & Prescribing Data
59 patients who switched from secukinumab to alternative biologics.
Ixekizumab may offer advantages in short- to mid-term effectiveness, particularly in secondary failure.
Clinical Best Practices
Consider the type of treatment failure (primary vs. secondary) when selecting a subsequent biologic.
Integrate patient preference and drug-specific characteristics into treatment decisions.
Application of newly proposed GRAPPA and EULAR criteria in a longitudinal cohort identified progressively smaller groups of patients with early psoriatic arthritis who experienced persistently worse patient-reported outcomes.
Genetically predicted triglyceride levels were associated with higher odds of psoriasis, while genetically predicted total fatty acid levels were not, in a two-sample Mendelian randomization analysis.
